the Hekimi LAB

Hekimi Lab: Industrial Applications

A number of insights that spring from our work have been applied in an industrial setting. Initially, from 1998 to 2008 by Chronogen Inc., a biotechnology drug-discovery company founded by Professor Hekimi, has used bacteria, worms, and mouse cells to screen for compounds able to impact the aging process and age-dependent diseases. Currently, we have entered a license agreement and a partnership with CLARUS Therapeutics Holdings Inc. for the clinical development of a new formulation for providing ubiquinone in an injectable form. We have shown that this formulation allows for the first time to reach supraphysiological levels of ubiquinone in all major organs.

Hekimi Lab: Industrial Patents

Patent Application in WIPO No. CA2019/050120
Formulations for improving the delivery of hydrophobic agents. Inventors: HEKIMI S, WANG Y.

Patent Application in European Patent Convention No. 19746864.8.
Formulations for improving the delivery of hydrophobic agents. Inventors: HEKIMI S, WANG Y.  

Docket number: G11168-00480-SSS.
Formulations for improving the delivery of hydrophobic agents. Inventors: HEKIMI S, WANG Y. US National application.

WO2008014602-A1; EP2079699-A1; IN200900629-P1

New substituted 8-hydroxyquinoline derivatives useful for treating e.g. cardiovascular diseases, cancer, Alzheimer's disease, stroke, pneumonia, arthritis, and hearing impairment. Inventors: HEKIMI S, MCBRIDE K, HIHI A K, et al.

WO2008058383-A1; EP1981493-A1; AU2007321667-A1
Composition, useful e.g. to prevent or reduce collagen deposition in a tissue and to treat or prevent scleroderma, keloids and hypertrophic scars, comprises an acyl-CoA:cholesterol O-acyltransferase inhibitor comprising e.g. avasimibe. Inventors: HEKIMI S, HIHI A K, BRANICKY R S, et al.

WO2006037224-A1; US2006088509-A1
New clk-1 -/- cell isolated from clk-1 heterozygous animal, useful for treating an oxidative stress disorder, e.g. amyotrophic lateral sclerosis, Alzheimer's disease, or age-related disorder. Inventors: HEKIMI S, LIU X X, JIANG N, et al.

WO2004099770-A1; US2004265989-A1; AU2004236777-A1
New prokaryotic or eukaryotic test cell, useful for screening modulators of 2 polyprenyl-3-methyl-6-methoxy-1,4-benzoquinone hydroxylase activity. Inventors: HEKIMI S, HIHI A, NADEAU G, et al.

WO2004081231-A1; US2004216174-A1; AU2004220003-A1
Isolating a gene that modulates the level of a lipid or lipoprotein comprises subjecting nematodes comprising mutation in the clk-1 gene to mutagenesis. Inventors: HEKIMI S, SHIBATA Y, BRANICKY R

WO2003014383-A; WO2003014383-A2; EP1417485-A2
Screening for compound allowing survival of clk1 homozygous mutant vertebrate embryos useful for treating diabetes, Parkinson's/Alzheimer's disease by breeding heterozygous clk1 subjects to obtain clk1 homozygous mutant embryos. Inventors: HEKIMI S, HIHI A, LEVAVASSEUR F, et al.

WO2003012133-A; WO2003012133-A2; EP1412527-A2
New isp-1 or ctb-1 genes and ISP-1 or CTB-1 proteins, useful for altering a cellular physiological function involved in developmental rates, behavioural rates, and longevity, or production of reactive oxygen species. Inventors: FENG J, BUSSIERE F, HEKIMI S.

EP1325124-A; WO200198478-A; WO200198478-A2
Novel genes clk-2, cex-7 and coq-4 useful to alter function at level of cellular physiology involved in developmental rate, telomere length and longevity and to increase life span of multicellular organism. Inventors: HEKIMI S, BENARD C, MCCRIGHT B, et al.

WO9910482-A; EP1009813-A; WO9910482-A1
Molecular identity of the gro-1 gene - useful for cancer diagnosis and/or prognosis, and where compounds affecting encoded proteins are useful for enhancing longevity of a host and inhibiting tumor formation. Inventors: HEKIMI S, LAKOWSKI B, BARNES T, et al.

WO9817823-A; EP932701-A; WO9817823-A1
New Caenorhabditis elegans clk-1 gene - used to obtain human clk-1 sequence, useful for, e.g. cancer diagnosis. Inventors: HEKIMI S, EWBANK J, BARNES T, et al.

US Provisional application (61858274)
Mouse Model Providing A Method For Identifying Substances To Alleviate Ubiquinone Deficiencies. HEKIMI S. WANG Y.